Beta 2 microglobulin Test

The beta-2 microglobulin test, also known as the beta-2 microglobulin tumour marker test, is a blood test that measures the level of beta-2 microglobulin in the blood.

Beta-2 microglobulin is a small protein found on the outer surface of most cells in the body. It is normally released into the blood and removed from the body by the kidneys.

Doctors use the beta-2 microglobulin test to help evaluate and monitor certain blood cancers, such as multiple myeloma, chronic lymphocytic leukaemia (CLL), and certain lymphomas. The test may also be used to assess autoimmune disorders and kidney function, as kidney disease can affect the body's ability to remove beta-2 microglobulin.

The beta-2 microglobulin test is not a routine screening test. It is usually performed when a person has been diagnosed with multiple myeloma, certain lymphomas, or chronic lymphocytic leukaemia (CLL), or when a doctor needs to assess kidney function or certain haematological malignancies.

This test may be recommended as a part of the evaluation when an individual has the following signs and symptoms:

• Unexplained fatigue, weight loss, and fever.
• Shortness of breath.
• Suspected chronic kidney disease.
• Abnormal blood test results suggestive of a blood disorder or kidney disease.

People who may need this test include the following:

• People diagnosed with multiple myeloma: The test helps assess the severity of the disease, estimate prognosis, and monitor how well treatment is working.
• People with certain blood cancers, such as lymphoma or chronic lymphocytic leukaemia (CLL): The beta-2 microglobulin multiple myeloma assessment may also be used to monitor disease activity and evaluate the response to treatment.
• Individuals with suspected or known kidney disease: The test may be recommended to assess kidney function in individuals with kidney disease or undergoing dialysis, as the kidneys normally remove beta-2 microglobulin from the blood.
• People undergoing treatment for blood cancers: Repeat testing may help doctors monitor disease activity and detect changes in response to treatment.
• Individuals with autoimmune conditions like Sjogren’s disease or immune conditions like HIV.
• People who have undergone kidney transplant: High levels of beta-2 microglobulin in blood may indicate that the transplanted organ is being rejected by the body.

The beta-2 microglobulin (B2M) test helps doctors assess the following conditions. The test is also useful for monitoring disease progression and response to treatment.

• Multiple myeloma: A cancer of plasma cells (a type of white blood cell) that develops in the bone marrow. Beta-2 microglobulin levels are commonly used to assess the stage of the disease, estimate prognosis, and monitor treatment response.
• Lymphoma: A group of cancers that affect the lymphatic system. Increased beta-2 microglobulin levels may indicate a higher tumour burden or more advanced disease.
• Chronic lymphocytic leukaemia (CLL): A slow-growing blood cancer that affects lymphocytes (a type of white blood cell). The test may help assess disease activity and prognosis.
• Kidney disease: Beta-2 microglobulin is normally removed from the blood by the kidneys. Increased blood levels may occur when kidney function is impaired, making the test useful as a part of kidney function evaluation.
• Autoimmune diseases and immune conditions: High beta-2 microglobulin in autoimmune diseases, such as rheumatoid arthritis and systemic lupus erythematosus, may indicate increased immune system activity. Infectious conditions such as HIV may also be associated with high beta-2 microglobulin levels.
• Transplant rejection: High levels of beta-2 microglobulin may indicate that the transplanted organ is being rejected by the body.

What to Expect Before the Beta 2 Microglobulin Test

No fasting is required for a standalone beta 2 microglobulin test. You can eat and drink normally. However, if it is part of a broader package that includes fasting tests, your doctor may advise fasting for 8-12 hours. Avoid strenuous exercise for 24 hours before the test, as intense physical activity can temporarily raise beta 2 microglobulin levels and affect interpretation. Always inform your doctor about any ongoing medications.

What to Expect During the Blood Collection

A phlebotomist cleans the skin with an antiseptic, then places an elastic band around your upper arm to make the veins easier to access. A small needle is inserted into the vein; you may feel a brief pinch. Blood is collected into a labelled tube in under a minute.

What to Expect After the Beta 2 microglobulin Test

A small cotton swab and bandage are placed over the site to stop any minor bleeding. You can return to normal activities immediately. Minor bruising is normal and disappears quickly. If dizzy, sit and rest for a few minutes.

The beta-2 microglobulin test measures only one parameter:

• The concentration of beta-2 microglobulin in the blood.

The normal range of beta-2 microglobulin may vary slightly depending on the laboratory and the testing method used. The normal range for beta-2 microglobulin is as follows:

The beta-2 microglobulin test measures the level of beta-2 microglobulin in the blood. The results should always be interpreted along with the patient's symptoms, medical history, kidney function tests, and other laboratory findings.

The beta-2 microglobulin test is generally safe because it requires only a blood sample. However, like all blood tests, it has certain minor risks, as follows.

• Mild pain, discomfort, minor bruising or slight bleeding at the needle insertion site.
• Rarely, dizziness, fainting, or infection may occur after blood collection.

Depending on the results of the beta-2 microglobulin test, your doctor may recommend additional tests to determine the underlying cause of abnormal beta-2 microglobulin levels and assess the extent of the disease or kidney involvement.

• Kidney function tests
• Urine beta-2 microglobulin test
• Complete blood count (CBC)
• Serum protein electrophoresis
• Immunofixation